The results of a unique dietary supplement (nutraceutical formulation) used to treat the symptoms of long-haul COVID

por Gaylis, Norman B., Kreychman, Ida, Sagliani, Joanne, Mograbi, Josef, Gabet, Yankel
Publicado 2022

Considering Immuno-autonomics in Stratifying Successful Treatment of Rheumatoid Arthritis with Tumor Necrosis Factor Inhibition: Comment on Cohen et al. Rheumatol Ther 2021 June 19

por Holman, Andrew J., Keystone, Edward, Choy, Ernest, Furst, Daniel, Taylor, Peter, Gaylis, Norman
Publicado 2021

Evaluating joint-space narrowing and cartilage loss in rheumatoid arthritis by using MRI

por Peterfy, Charles G, DiCarlo, Julie C, Olech, Ewa, Bagnard, Maire-Agnes, Gabriele, Annarita, Gaylis, Norman
Publicado 2012

Monitoring cartilage loss in the hands and wrists in rheumatoid arthritis with magnetic resonance imaging in a multi-center clinical trial: IMPRESS (NCT00425932)

por Peterfy, Charles G, Olech, Ewa, DiCarlo, Julie C, Merrill, Joan T, Countryman, Peter J, Gaylis, Norman B
Publicado 2013

Patient-reported outcome assessment of inflammatory arthritis patient experience with intravenously administered biologic therapy

por Gaylis, Norman B, Sagliani, Joanne, Black, Shawn, Tang, Kezhen L, DeHoratius, Raphael, Kafka, Wesley A, Parenti, Dennis
Publicado 2017

Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study

por Pritchard, Charles H, Greenwald, Maria W, Kremer, Joel M, Gaylis, Norman B, Rigby, William, Zlotnick, Steve, Chung, Carol, Jaber, Birgit, Reiss, William
Publicado 2014

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Ph...

por Blauvelt, Andrew, Leonardi, Craig L., Gaylis, Norman, Jauch-Lembach, Julia, Balfour, Alison, Lemke, Lena, Hachaichi, Sohaib, Brueckmann, Ines, Festini, Teodora, Wiland, Piotr
Publicado 2021

Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective p...

por Emery, Paul, Mease, Philip J., Rubbert-Roth, Andrea, Curtis, Jeffrey R., Müller-Ladner, Ulf, Gaylis, Norman B., Williams, Sarah, Reynard, Mark, Tyrrell, Helen
Publicado 2011

Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, rand...

por Smolen, Josef S, Kay, Jonathan, Doyle, Mittie, Landewé, Robert, Matteson, Eric L, Gaylis, Norman, Wollenhaupt, Jürgen, Murphy, Frederick T, Xu, Stephen, Zhou, Yiying, Hsia, Elizabeth C
Publicado 2015

Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, doub...

por Smolen, Josef S, Kay, Jonathan, Landewé, Robert B M, Matteson, Eric L, Gaylis, Norman, Wollenhaupt, Jurgen, Murphy, Frederick T, Zhou, Yiying, Hsia, Elizabeth C, Doyle, Mittie K
Publicado 2012

Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized,...

por Wiland, Piotr, Jeka, Sławomir, Dokoupilová, Eva, Brandt-Jürgens, Jan, Miranda Limón, Juan Manuel, Cantalejo Moreira, Miguel, Cabello, Raul Veiga, Jauch-Lembach, Julia, Thakur, Anjali, Haliduola, Halimuniyazi, Brueckmann, Ines, Gaylis, Norman B.
Publicado 2020